



L4 ANSWER 1 OF 4 USPATFULL
 ACCESSION NUMBER: 2000:80434 USPATFULL
 TITLE: Process for encapsulation of caplets in a capsule and
 INVENTOR(S): solid dosage forms obtainable by such process
 Amey, James, Greenwood, SC, United States
 Cade, Dominique, Colmar, France
 Maes, Paul, Mortsel, Belgium
 Scott, Robert, Waasmunster, Belgium
 PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6080426	20000627
APPLICATION INFO.:	US 1996-585549	19960111 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-358137, filed on 16	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Spear, James M.
 LEGAL REPRESENTATIVE: Almer, Charles W.
 NUMBER OF CLAIMS: 38
 EXEMPLARY CLAIMS: 1
 LINE COUNT: 456
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such process are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.
 IT 34031-32-8, Auranofoin (encapsulation of caplets in capsules in tamper-proof forms)
 RN 34031-32-8 USPATFULL
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato] (triethylphosphine)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 USPATFULL (Continued)
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato] (triethylphosphine)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 USPATFULL
 ACCESSION NUMBER: 1999:155217 USPATFULL
 TITLE: Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition
 INVENTOR(S): De Lacharriere, Olivier, Paris, France
 Breton, Lionel, Versailles, France
 Cohen, Catherine, Paris, France
 PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, France (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5993833	19991130
APPLICATION INFO.:	US 1997-879889	19970620 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-580291, filed on 28 Dec 1995, now patented, Pat. No. US 5658581	

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-15796	19941228
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Venkat, Jyothsna	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	745	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthetic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents.
 IT 34031-32-8, Auranofoin (pharmaceutical and cosmetic comps. contg. histamine and interleukin and .alpha.-tumor necrosis factor antagonists)
 RN 34031-32-8 USPATFULL


L4 ANSWER 3 OF 4 USPATFULL
 ACCESSION NUMBER: 97:73298 USPATFULL
 TITLE: Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained
 INVENTOR(S): De Lacharriere, Olivier, Paris, France
 Breton, Lionel, Versailles, France
 Cohen, Catherine, Paris, France
 PATENT ASSIGNEE(S): L'Oreal, Paris, France (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5658581	19970819
APPLICATION INFO.:	US 1995-580291	19951228 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-15796	19941228
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Venkat, Jyothsna	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1,8	
LINE COUNT:	666	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthetic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents.
 IT 34031-32-8, Auranofoin (pharmaceutical and cosmetic comps. contg. histamine and interleukin and .alpha.-tumor necrosis factor antagonists)
 RN 34031-32-8 USPATFULL
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato] (triethylphosphine)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 USPATFULL (Continued)



L4 ANSWER 4 OF 4 USPATFULL

ACCESSION NUMBER: 96:53294 USPATFULL
 TITLE: Topically applied gold organic complex
 INVENTOR(S): Papandrea, Ralph A., Collaroy, Australia
 PATENT ASSIGNEE(S): Top Gold Pty Limited, Collaroy, Australia (non-U.S. corporation)

NUMBER	DATE
US 5527779	19960618
US 1994-215409	19940318 (8)
Continuation of Ser. No. US 1991-576385, filed on 15 Aug 1991, now abandoned	

NUMBER	DATE
AU 1988-7387	19880323
AU 1988-7480	19880328
AU 1988-9878	19880815
AU 1989-2313	19890118


DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Robinson, Douglas W.
 ASSISTANT EXAMINER: White, Everett
 LEGAL REPRESENTATIVE: Nikaido Marmelstein Murray & Oram
 NUMBER OF CLAIMS: 28
 EXEMPLARY CLAIM: 1
 LINE COUNT: 496

AB It has been surprisingly found that gold compounds may be applied in topical preparations as an effective treatment of local or systemic inflammatory conditions and/or as antibacterial agents. The present invention therefore relates to new pharmaceutical compositions containing gold for topical application, and the use of the composition in treating inflammation and/or bacterial infection.

IT 34031-32-8, Aurano-fin
 (ointments, formulation of, as bactericides and inflammation inhibitors)

RN 34031-32-8 USPATFULL

CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 USPATFULL (Continued)

=>

=> d ibib ab hitstr 1-14


L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 2000:534811 CAPLUS
TITLE: Implantable medical device with enhanced
biocompatibility and biostability
INVENTOR(S): Fernandes, Brian C. A.; Donovan, Maura G.; Sparer,
Randall V.; Casas-Bejar, Jesus W.; Torrianni,
Mark W.
PATENT ASSIGNEE(S): Medtronic Inc., USA
SOURCE: Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1023879	A2	20000802	EP 2000-101782	20000128

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: US 1999-117837 19990129
US 1999-301842 19990429

AB An implantable medical device comprising a drug-loaded polymer overlaid with a fabric that promotes tissue ingrowth is useful in a wide variety of tissue engineering applications. The invention includes, for example, prosthetic heart valves, annuloplasty rings, and grafts, having enhanced biocompatibility and biostability. Methods of making and using the implantable medical devices of the invention are also included. An example was given showing in vitro modulation of macrophage phenotype on dexamethasone-loaded polymer (Pellethane 80A) and its effect on polymer stability in a human macrophage/Fe/stress system.
IT 34031-32-8, Auranofin
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(implantable medical device with enhanced biocompatibility and biostability)
RN 34031-32-8 CAPLUS
CN Gold, [1-(thio-kappa-S)-beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:279689 CAPLUS
DOCUMENT NUMBER: 130:316634
TITLE: Intraarticular preparation for treatment of arthropathy
INVENTOR(S): Suzuki, Makoto; Ishigaki, Kenji; Okada, Minoru; Ono, Kenji; Kasai, Shuichi; Imamori, Katsumi
PATENT ASSIGNEE(S): SSP Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 911025	A1	19990428	EP 1998-119414	19981014

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,

PT, IE, SI, LT, LV, FI, RO
JP 11222425 A2 19990817 JP 1998-293385 19981015
CN 1215589 A 19990505 CN 1998-124109 19981027
PRIORITY APPLN. INFO.: JP 1997-294009 19971027
AB This invention relates to an intra-articular prepn. for the treatment of arthropathy, which comprises microcapsules of (a) a high-mol. substance, which has biodegradability and biocompatibility, and (b) a drug. When applied directly to a joint area, this prepn. can achieve a high drug concn. at the target area, can inhibit occurrence of general side effect, and can maintain drug efficacy over a long term. The prepn. can therefore alleviate the burden on the patient. Microcapsules were prepd. from lactic acid-glycolic acid copolymer 4.5, beclomethasone propionate 0.5 g and other ingredients, and their particle sizes and pharmacokinetic parameters were tested.
IT 34031-32-8, Auranofin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intraarticular prepn. for treatment of arthropathy contg. microcapsules of high-mol. substances and pharmaceutically active agents)
RN 34031-32-8 CAPLUS
CN Gold, [1-(thio-kappa-S)-beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)


L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)

REFERENCE COUNT: 9
REFERENCE(S): (1) Boehringer Ingelheim Kg; EP 0400522 A2 1990
CAPLUS
(2) Brodack, J; US 5320824 A 1994 CAPLUS
(3) Day, Dr US 5403573 A 1995 CAPLUS
(5) Jernberg, G; WO 91/17744 A1 1991 CAPLUS
(8) Takeda Chemical Industries, Ltd; EP 0442671 A2 1991 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:789026 CAPLUS
 DOCUMENT NUMBER: 130:20568
 TITLE: Treating asthma by preventing and/or
 accommodating for
 S-nitrosothiol breakdown
 INVENTOR(S): Gaston, Benjamin; Stamler, Jonathan S.; Griffith,
 Owen
 W.
 PATENT ASSIGNEE(S): Duke University, USA; The Medical College of
 Wisconsin
 Research Foundation, Inc.; University of Virginia
 Patent Foundation
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852580	A1	19981126	WO 1998-US8978	19980507
W: AU, CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9872801	A1	19981211	AU 1998-72801	19980507
PRIORITY APPLN. INFO.: US 1997-47336 19970521 US 1998-81740 19980415 US 1998-81470 19980415 WO 1998-US8978 19980507				
AB Asthma is ameliorated and mild or moderate asthma is prevented from progressing to more severe asthma by administering agents which prevent and/or accommodate for S-nitrosothiol breakdown, e.g. inhibitors of gamma-glutamyl transpeptidase or xanthine oxidase, chelators of copper and/or heme or non-heme iron, and NO donors. Thus, administration of a 10 mM soln. of bathocuproine disulfonate via inhalation as an aerosol at a dose of 0.01 mL/kg improve symptoms in a 24-yr old woman with severe asthma with symptoms of dyspnea on exertion, cough, and prolonged expiration. The method reduces requirements for systemic corticosteroids for the treatment of severe asthma.				
IT 34031-32-8, Auranofin RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibitors of S-nitrosothiol breakdown and NO donors for asthma treatment)				
RN 34031-32-8 CAPLUS				
CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-				

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 tetracetato)(triethylphosphine)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2
 REFERENCE(S): (1) Stamler; US 5380758 A 1995 CAPLUS
 (2) Stamler; US 5574068 A 1996


L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:426206 CAPLUS
 DOCUMENT NUMBER: 129:169939
 TITLE: How does auranofin compare with methotrexate and cyclosporin as a corticosteroid-sparing agent in severe asthma?
 AUTHOR(S): Bernstein, I. Leonard; Bernstein, David I.;
 Jonathan A.
 CORPORATE SOURCE: University of Cincinnati Medical Center,
 Cincinnati,
 OH, USA
 SOURCE: BioDrugs (1997), 6 (3), 205-215
 CODEN: BIDRF4; ISSN: 1173-8804
 PUBLISHER: Adis International Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 62 refs. Despite optimal anti-inflammatory treatment of asthma, including use of high dosage, high potency inhaled corticosteroids, a subset of corticosteroid-dependent patients require substantial amts. of daily systemic corticosteroids for adequate control. Several anti-inflammatory modulating agents (auranofin, methotrexate and cyclosporin) have been evaluated for their corticosteroid-sparing properties under such circumstances. This anal. was gleaned primarily from randomized, double-blind, placebo-controlled trials of these agents. Global assessment of corticosteroid-sparing efficacy of these drugs revealed an advantage of auranofin over both methotrexate and cyclosporin. In addn., the comparative adverse event profiles of these drugs indicated that auranofin exhibited milder, more tolerable adverse effects. Therefore, auranofin presents a better risk: benefit option in initial attempts to wean dependent patients from corticosteroids.




L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:323140 CAPLUS
 DOCUMENT NUMBER: 129:19685
 TITLE: Synergistic gold and corticosteroid-containing compositions
 INVENTOR(S): Thomas, Richard Edward
 PATENT ASSIGNEE(S): Medical Innovations Ltd., Australia; Thomas, Richard
 Edward
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9819683	A1	19980514	WO 1997-AU747	19971104
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, ML, MR, NE, SN, TD, TG				
AU 9747671	A1	19980529	AU 1997-47671	19971104
EP 954321	A1	19991110	EP 1997-910157	19971104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, PT, IE CN 1235550 A 19991117 CN 1997-199438 19971104				
PRIORITY APPLN. INFO.: AU 1996-3473 19961104 WO 1997-AU747 19971104				
AB This invention relates to a method of treating an immune-mediated disorder having one or more manifestations. The method comprises administering to a patient requiring such treatment a gold compd. and at least one corticosteroid, wherein the at least one corticosteroid is selected to interact synergistically with the gold compd. to exhibit preferential action towards one of the manifestations of said disorder or to exhibit equal action towards each manifestation of said disorder. The invention also relates to a pharmaceutical compn. suitable for use in the method. The synergistic effect of auranofin with various corticosteroids was demonstrated with betamethasone dipropionate, fluocinolone acetonide and mometasone furoate being particularly effective in reducing epidermal hyperplasia and				

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 inflammation.
 IT 34031-32-8, Auranofin
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (synergistic gold and corticosteroid-contg. compns.)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-
 tetraacetato] (triethylphosphine)- (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 or essentially no expansion and cut into discrete, relatively dense
 the particles. Release properties may also be controlled by precoating
 the encapsulant and/or coating the extruded particles with a film-forming
 component. An example of encapsulation of acetylcysteine is given
 using starch, polyethylene, glycerol monostearate, and vegetable oil.
 IT 34031-32-8, Auranofin
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses)
 (embedding and encapsulation of controlled release particles)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-
 tetraacetato] (triethylphosphine)- (9CI) (CA INDEX NAME)




L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:293427 CAPLUS
 DOCUMENT NUMBER: 129:8597
 TITLE: Embedding and encapsulation of controlled release
 particles
 INVENTOR(S): Van Lengerich, Bernhard H.
 PATENT ASSIGNEE(S): Van Lengerich, Bernhard H., USA
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818610	A1	19980507	WO 1997-US18984	19971027
W: AU, CA, JP, NO, PL, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE				
AU 9749915	A1	19980522	AU 1997-49915	19971027
EP 935523	A1	19990818	EP 1997-912825	19971027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT,				
IE, FI				
NO 9902036	A	19990428	NO 1997-2036	19990428
PRIORITY APPL. INFO.:			US 1996-29038	19961028
			US 1997-52717	19970716
			WO 1997-US18984	19971027

AB Controlled release, discrete, solid particles which contain an
 encapsulated and/or embedded component such as a heat sensitive or
 readily oxidizable pharmaceutically, biol., or nutritionally active component
 are continuously produced without substantial destruction of the matrix
 material or encapsulant. A release-rate controlling component is
 incorporated into the matrix to control the rate of release of the
 encapsulant from the particles. The addnl. component may be a
 hydrophobic component or a high water binding capacity component for extending the
 release time. The plasticizable matrix material, such as starch, is
 admixed with at least one plasticizer, such as water, and at least one
 release-rate controlling component under low shear mixing conditions
 to plasticize the plasticizable material without substantially
 destroying the at least one plasticizable material and to obtain a substantially
 homogeneous plasticized mass. The plasticizer content is
 substantially reduced and the temp. of the plasticized mass is substantially reduced
 prior to admixing the plasticized mass with the encapsulant to avoid
 substantial destruction of the encapsulant and to obtain a formable,
 extrudable mixt. The mixt. is extruded through a die without
 substantial

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:87949 CAPLUS
 DOCUMENT NUMBER: 128:123562
 TITLE: A simple inflammation model that distinguishes
 between the actions of anti-inflammatory and
 anti-rheumatic drugs
 AUTHOR(S): Lewis, E. J.; Bishop, J.; Aspinall, S. J.
 CORPORATE SOURCE: Roche Discovery Welwyn, Welwyn Garden City, AL7
 3AT, UK
 SOURCE: Inflammation Res. (1998), 47(1), 26-35
 CODEN: INREB; ISSN: 1023-3830
 PUBLISHER: Birkhauser Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effects of anti-inflammatory and anti-rheumatic drugs on paw
 swelling and changes in plasma levels of acute phase proteins (APPs) during
 acute inflammation in the rat was investigated. Inflammation was induced in
 rats by the injection of adjuvant and the animals were bled five days
 later and plasma levels of serumcoid, haptoglobin, ceruloplasmin and
 albumin were detd. spectrophotometrically using a Cobas-bio
 centrifugal analyzer. The effects of daily administration of a variety of drugs
 used to treat arthritis were detd. on paw swelling and APP levels.
 Injection of the adjuvant induced a pronounced change in APP levels which
 correlated with the increase in paw swelling. In general, the NSAIDs tested
 significantly reduced paw swelling and significantly increased levels
 of haptoglobin and ceruloplasmin in a dose-related manner. Two
 dose-levels of steroids were administered, the higher dose reduced swelling, and
 reduced levels of serumcoid, haptoglobin and ceruloplasmin, but
 raised albumin levels; the lower dose also reduced paw swelling, but the only
 change in APPs was increased albumin levels. Anti-rheumatic drugs
 such as gold salts reduced levels of some APPs (serumcoid, haptoglobin and
 ceruloplasmin) without reducing paw swelling. Immunomodulators had a
 variety of effects on inflammation and APPs depending on mechanism of
 action. It is concluded that the different classes of
 anti-inflammatory/anti-rheumatic drug tested show distinct profiles of
 activity against APPs and paw swelling. These differential effects
 may result from modulation of cytokine activity.
 IT 34031-32-8, Auranofin
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (a simple inflammation model distinguishes between the actions of
 anti-inflammatory and anti-rheumatic drugs)
 RN 34031-32-8 CAPLUS


L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1997:684253 CAPLUS
 DOCUMENT NUMBER: 127:336649
 TITLE: Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by this process
 INVENTOR(S): Cade, Dominique; Maes, Paul; Scott, Robert
 PATENT ASSIGNER(S): Warner-Lambert Co., USA
 SOURCE: PCR Int. Appl., 24 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9737629	A1	19971016	WO 1997-US4482	19970324
W: AL, CA, CN, JP, KR, LT, LV, MX, NO, RO, SI				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2250017	AA	19971016	CA 1997-2250017	19970324
EP 891180	A1	19990120	EP 1997-916858	19970324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1215322	A	19990428	CN 1997-193572	19970324
JP 2000508552	T2	20000711	JP 1997-536220	19970324
PRIORITY APPLN. INFO.: US 1996-628823 19960405				
WO 1997-US4482 19970324				
AB A process for encapsulation of caplets in a capsule comprises the following steps: (a) providing empty capsule parts; (b) filling at least one of the capsule parts with one or more caplets; (c) putting the capsule parts together; and (d) treating the combined parts by cold shrinking. The solid dosage forms obtainable by such a process are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.				
IT 34031-32-8, Auranofoin				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (process for encapsulation of caplets in capsules)				
RN 34031-32-8 CAPLUS				
CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)				

L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)




L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1997:520401 CAPLUS
 DOCUMENT NUMBER: 127:214792
 TITLE: Pharmacological influence of antirheumatic drugs on proteoglycanases from interleukin-1 treated articular cartilage
 AUTHOR(S): Steinmeyer, Juergen; Daufeldt, Sabine
 CORPORATE SOURCE: Department of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, 53113, Germany
 SOURCE: Biochem. Pharmacol. (1997), 53(11), 1627-1635
 CODEN: BCPA6; ISSN: 0006-2952
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The purpose of this study was to examine whether drugs used in the treatment of arthritic disorders possess any inhibitory potential on the proteoglycanolytic activities of matrix metalloproteinases (MMPs), and to det. whether drugs which inhibit these enzymes also modulate the biosynthesis and release of proteoglycans (PGs) from interleukin-1 (IL-1) treated articular cartilage explants. The cartilage-bone marrow ext. and the glycosaminoglycan-peptide complex (DAK-16) dose-dependently inhibited MMP proteoglycanases in vitro when tested at concns. ranging from 0.5 to 55 mg/mL, displaying an IC50 value of 31.78 mg/mL and 10.64 mg/mL (1.9 times. 10-4 M) resp.
 (R,S)-N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl-L-phenylalaninamide (U-24522) proved to be a potent inhibitor of MMP proteoglycanases (IC50 value 1.8 times. 10-9 M).
 None of the other tested drugs, such as possible chondroprotective drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic drugs (DMARDs), glucocorticoids and angiotensin-converting enzyme inhibitors tested at a concn. of 10-4 M displayed any significant inhibition. Only U-24522, tested at a concn. ranging from 10-4 to 10-6 M, significantly inhibited the IL-1-induced augmentation of PG loss from cartilage explants into the nutrient media, whereas DAK-16 and the cartilage-bone marrow ext. were ineffective. DAK-16 and the cartilage-bone marrow ext. did not modulate the IL-1-mediated reduced biosynthesis and aggregability of PGs by the cartilage explants. The addn. of 10-5 M U-24522, however, partially maintained the aggregability of PGs ex vivo. In our expts., both possible chondroprotective drugs as well as U-24522 demonstrated no cytotoxic effects on chondrocytes.

L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 IT 34031-32-8, Auranofin
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effects of antirheumatic drugs on proteoglycanases from interleukin-1 treated articular cartilage)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)




L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 IT 34031-32-8, Auranofin
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (auranofin effect on COX-1- and COX-2-dependent PGE2 prodn. in relation to mechanism of antirheumatic and antiinflammatory activities)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio-.kappa.S)-.beta.-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)




L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1997:318911 CAPLUS
 DOCUMENT NUMBER: 127:13186
 TITLE: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages
 AUTHOR(S): Yamada, Masateru; Niki, Hisae; Yamashita, Mue, Suetsugu; Ohuchi, Kazuo
 CORPORATE SOURCE: Department Pathophysiological Biochemistry, Pharmaceutical Sciences, Tohoku University, Sendai, Japan
 SOURCE: J. Pharmacol. Exp. Ther. (1997), 281(2), 1005-1012
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Rat peritoneal macrophages were incubated in the presence of cycloheximide or dexamethasone to inhibit the induction of cyclooxygenase (COX)-2 protein synthesis. Thereafter, when the macrophages were incubated in the presence of arachidonic acid, PGE2 prodn. was increased. Western blot anal. demonstrated that COX-2 protein levels were low and were not affected by arachidonic acid treatment. COX-1 protein levels were not affected by arachidonic acid treatment either. The COX-2 inhibitors NS-398 and nimesulide only slightly inhibited PGE2 prodn., whereas the COX-1/COX-2 inhibitors indomethacin, piroxicam and tenoxicam strongly inhibited PGE2 prodn. This suggests that under these conditions, PGE2 prodn. is dependent on COX-1. After the macrophages were treated with aspirin to inactivate existing COX-1 and COX-2, however, treatment with 12-O-tetradecanoylphorbol 13-acetate increased PGE2 prodn. Furthermore, COX-2 protein levels were markedly increased by 12-O-tetradecanoylphorbol 13-acetate treatment, whereas COX-1 protein levels did not change. In this case, both the COX-2 and the COX-1/COX-2 inhibitors inhibited PGE2 prodn. This suggests that under these conditions, PGE2 prodn. is dependent on COX-2. Effects of auranofin on COX-1-dependent and COX-2-dependent PGE2 prodn. were examd. We found that auranofin stimulated COX-1-dependent PGE2 prodn. but inhibited COX-2-dependent PGE2 prodn. in a concn.-dependent manner. The latter effect was found to be due to the inhibition of COX-2 protein induction. These findings might explain the mechanism of the antirheumatic and anti-inflammatory activities of auranofin.

L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:587923 CAPLUS
 DOCUMENT NUMBER: 125:265598
 TITLE: A placebo-controlled multicenter study of the treatment of patients with corticosteroid-dependent asthma
 AUTHOR(S): Bernstein, I. Leonard; Bernstein, David I.; Dubb, Jeffrey W.; Faerman, Isidore; Wallin, Bruce; Bronsky, Edwin; Spector, Sheldon L.; Nathan, Robert
 CORPORATE SOURCE: A. J. Nelson, Harold S., et al. College Medicine, University Cincinnati, Cincinnati, OH, 45267, USA
 SOURCE: J. Allergy Clin. Immunol. (1996), 98(2), 317-324
 CODEN: JACIBY; ISSN: 0091-6749
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Previous clin. studies have demonstrated that injectable gold salts and the oral gold compd., auranofin, possess significant steroid-sparing effects in the treatment of asthma. Objectives: The objectives of this investigation were to det. whether auranofin could reduce oral corticosteroid requirements and to evaluate the safety of auranofin in the treatment of chronic corticosteroid-dependent asthma. Methods: Patients with asthma were eligible if they required at least 10 mg of prednisone per day for control and prevention of asthma exacerbations. Two hundred seventy-nine patients with chronic corticosteroid-dependent asthma (requiring .gtoreq. 10 mg/day) were randomized to receive auranofin, 3 mg twice daily, or placebo during an 8-mo clin. trial, which was divided into three phases including: a 4-wk baseline period (phase I), a 6-mo double-blind treatment and steroid redn. period (phase II), and a 4-wk posttreatment observation period during which steroid and auranofin doses or placebo doses were maintained at levels achieved by the end of phase II (phase III). The primary efficacy variable was "therapeutic success" or redn. of daily corticosteroid use by 50% or more. Results: The proportion of patients in the auranofin group achieving therapeutic success (41%) was significantly higher than that in the placebo group (27%) (p = 0.01). This effect was greatest in patients requiring 10 to 19 mg of oral prednisone per day at baseline (p < 0.001). In all treated patients, including those who did and did not complete the trial, significant redn. (.gtoreq. 50% of baseline) in oral corticosteroid dosage was achieved in the auranofin group (60%) compared with the placebo group (32%) (p < 0.001). There were no significant differences between treatment groups in symptoms, concomitant medication use, or lung function. Mean serum total IgE levels decreased significantly from baseline in the auranofin group (-44.63 IU/mL) compared with the placebo

L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 group ($p = 0.001$). Gastrointestinal and cutaneous adverse events were greater in the auranofin group. Conclusions: Auranofin demonstrated a steroid-sparing effect without concomitant worsening of symptoms or lung function and appeared to be more effective in patients dependent on 10 to 19 mg of prednisone per day. Therefore this study has demonstrated that auranofin is useful as a steroid-sparing agent in the treatment of chronic corticosteroid-dependent asthma.
 IT 34031-32-8, Auranofin
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (placebo-controlled multicenter study of auranofin in the treatment of humans with corticosteroid-dependent asthma)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio- κ .S)- β .-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)



L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)




L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:464557 CAPLUS
 DOCUMENT NUMBER: 125:96163
 TITLE: Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
 INVENTOR(S): Amey, James; Cade, Dominique; Maes, Paul; Scott, Robert
 PATENT ASSIGNER(S): Warner-Lambert Company, USA
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9618370	A1	19960620	WO 1995-US14651	19951109
W: CA, CN, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 797424	A1	19971001	EP 1995-939890	19951109
EP 797424	B1	20000712		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE				
CN 1170346	A	19980114	CN 1995-196811	19951109
JP 11500326	T2	19990112	JP 1995-518819	19951109
AT 194486	E	20000715	AT 1995-939890	19951109
US 6080426	A	20000627	US 1996-585549	19960111
CA 2214923	AA	19990309	CA 1997-2214923	19970909
PRIORITY APPLN. INFO.:			US 1994-358137	19941216
			WO 1995-US14651	19951109

AB A process for encapsulation of caplets in a capsule comprises the following steps: (a) providing empty capsule parts; (b) filling at least one of the capsule parts with one or more caplets; (c) putting the capsule parts together, and (d) treating the combined parts by cold shrinking. The solid dosage forms obtainable by such a process are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.
 IT 34031-32-8, Auranofin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (encapsulation of caplets in capsules in tamper-proof forms)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio- κ .S)- β .-D-glucopyranose 2,3,4,6-tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)


L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:375709 CAPLUS
 DOCUMENT NUMBER: 125:48726
 TITLE: Type II collagen-induced arthritis in the diabetic-resistant BioBreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process
 AUTHOR(S): Smith, Robert J.; Sly, Laurel M.
 CORPORATE SOURCE: Dep. Cell Biol. Inflammation Res., Pharmacia & Upjohn, Inc., Kalamazoo, MI, USA
 SOURCE: J. Pharmacol. Exp. Ther. (1996), 277(3), 1801-1813
 CODEN: JPETAB; ISSN: 0022-3565
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Diabetic-resistant (DR) BioBreeding (BB) rats developed an erosive hind paw arthritis when immunized with an emulsion of bovine type II collagen (CII) and incomplete Freund's adjuvant. Macroscopic clin. evidence of type II collagen-induced arthritis (CIA) first appeared as periarticular erythema and edema in the hind paws between days 9 and 10 post-immunization with CII. The incidence of CIA was 100% by day 11 in the CII-challenged rats; and CIA severity progressed over a 28-day period with radiog. evaluation revealing focal resorption of bone together with osteophyte formation in the tibiotarsal joint and soft tissue swelling; the histopathol. of CIA included an hyperplastic synovium that invaded and eroded articular cartilage at the joint margins, and subchondral bone resorption assoc. with bone-derived, multinucleated cell-conty. granulomatous lesions in the rat hind paw. The corticosteroid, methylprednisolone (medrol), and the nonsteroidal antiinflammatory drug, flurbiprofen (Ansaid), administered at 2 mg/kg (p.o.), suppressed the clin. signs of CIA, and caused 79 to 83% inhibition of hind paw inflammation. However, methylprednisolone, but not flurbiprofen, inhibited the joint pathol. in CIA. The antirheumatic drugs, cyclophosphamide (cytoxan, 5 mg/kg, p.o.) and cyclosporin A (CsA, 25 mg/kg, p.o.) suppressed the cartilage erosion in inflamed rat joints, and exerted marked inhibition (89-100%) of hind paw swelling.
 Methotrexate (0.15 mg/kg, p.o.) treatment reduced hind paw swelling (48%), whereas azathioprine, D-penicillamine (DP) and the oral gold prepn., auranofin, were inactive. Anti-CII antibody titers were completely suppressed by cyclosporin A and cytoxan. Radiog. evidence of protection from bone resorption, osteophyte formation and soft tissue swelling was apparent in

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 the tibiotarsal joints of cytoxan, cyclosporin A, methylprednisolone
 and
 methotrexate-treated rat.
 IT 34031-32-8, Auranofin
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (type II collagen-induced arthritis in the diabetic-resistant
 BioBreeding rat: histopathol. features of joint pathol. and
 effects of
 antiinflammatory and antirheumatic drugs)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio-kappa.S)-.beta.-D-glucopyranose 2,3,4,6-
 tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1995:436882 CAPLUS
 DOCUMENT NUMBER: 122:255792
 TITLE: A simple in vivo model of collagen degradation
 using
 collagen-gelled cotton buds: the effects of
 collagenase inhibitors and other agents
 AUTHOR(S): Karran, Eric H.; Dodgson, Kathryn; Harris, Sonia
 J.;
 Mackwell, Roger E.; Harper, Gregory P.
 CORPORATE SOURCE: SmithKline Beecham Pharmaceuticals, Essex, CM19
 5AW,
 UK
 SOURCE: Inflammation Res. (1995), 44(1), 36-46
 CODEN: INREFF; ISSN: 1023-3830
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A simple in vivo model of collagen degra. has been developed, and the
 effects of various agents have been tested. Type I collagen was
 prepd.
 from rat skin and acetylated with either [3H]- or [14C] acetic
 anhydride.
 The radiolabeled collagen was added to sterile cotton buds and
 incubated
 at 37 .degree.C to allow the collagen to form native fibrils that were
 firmly adsorbed to the cotton matrix. After s.c. implantation of the
 collagen-gelled cotton buds into rats, the radiolabeled collagen was
 progressively removed over a period of weeks by an infiltrating
 granuloma.
 Of the agents that were administered directly into the cotton buds
 using
 s.c. implanted osmotic mini-pumps, only the synthetic collagenase
 inhibitors CI-A (contg. a hydroxamate moiety as a zinc ligand) and
 CI-C
 (contg. a thiol moiety as a zinc ligand) were able to prevent the
 removal
 of collagen: their efficacy correlated with the level of collagenase
 inhibitory activity assayed in the exudate fluid sequestered within
 the
 cotton bud granuloma. Of the agents that were administered
 systemically,
 including anti-inflammatory drugs and other compds. used as therapies
 for
 arthritis, only hydrocortisone was able to inhibit the removal
 of radiolabeled collagen. These results suggest that, in this model,
 interstitial collagenase, a member of the matrix metalloproteinase
 family,
 comprised the major degradative pathway for collagen. The
 collagen-gelled
 cotton bud model is a useful test system for delineating those
 processes
 that result in collagen catabolism. In addn., the model can be used
 for

L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2000 ACS (Continued)
 testing agents, including those of limited or unknown systemic
 bioavailability, in order to discover novel therapeutic agents for
 preventing collagen degra. in connective tissue diseases such as
 arthritis.
 IT 34031-32-8, Auranofin
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (collagen-gelled cotton buds model of collagen degra. and
 collagenase
 inhibitors and other agents effects)
 RN 34031-32-8 CAPLUS
 CN Gold, [1-(thio-kappa.S)-.beta.-D-glucopyranose 2,3,4,6-
 tetraacetato](triethylphosphine)- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:24:37 ON 23 AUG 2000)

FILE 'REGISTRY' ENTERED AT 10:24:41 ON 23 AUG 2000
L1 1 SS AURANOFIN/CN

FILE 'USPATFULL' ENTERED AT 10:24:54 ON 23 AUG 2000
L2 20 S L1
L3 0 S L2 (P)CORTICOSTEROID?
L4 4 S L2 AND (HYDROCORTISONE OR BETAMETHASONE OR DEXAMETHASONE OR
M

FILE 'CAPLUS' ENTERED AT 10:29:12 ON 23 AUG 2000
L5 80 S L1/THU
L6 10 S L5 AND (HYDROCORTISONE OR BETAMETHASONE OR DEXAMETHASONE OR ..
M
L7 5 S L5 AND CORTICOSTEROID?
L8 14 S L6 OR L7